Brazilian envoy praises standards of Eskayef plant
Brazil's Ambassador to Bangladesh Joao Tabajara de Oliveira Junior has highly appreciated Eskayef Pharmaceuticals' foresight for Covid-19 management, especially the initiative to launch Remdesivir, which has been approved for treating coronavirus patients.
During a visit to Eskayef's manufacturing facility in Tongi yesterday, Oliveira said he was pleased to see that the plant is being established at a standard similar to that of first world countries.
For all latest news, follow The Daily Star's Google News channel. "The state-of-the-art manufacturing plant and its passionate professionals make Eskayef a world class company here in Bangladesh," he said.
"The pharmaceutical industry is one of the most promising export industries of Bangladesh. And Eskayef has all the potential to export generic pharmaceutical products to Brazil and other countries of the world," Oliveira added.
The ambassador was welcomed by Simeen Rahman, managing director and CEO of Eskayef Pharmaceuticals and also group CEO of Transcom.
Oliveira visited various units of the Faraaz Ayaaz Hossain Building, where he was briefed on the world-class technologies and operational excellence present at the manufacturing facility.
"Bangladesh and the whole world is facing an unprecedented challenge due to the coronavirus pandemic," Rahman said.
Eskayef's core competency lies in manufacturing international standard sterile products.
During the darkest time of the coronavirus outbreak, when there was no effective drug to treat Covid-19 patients, Eskayef launched Remdesivir, which has not only served the patients of Bangladesh but also many other countries.
"At Eskayef, we have a firm commitment to make every possible Covid-19 treatment available for the people of Bangladesh. We will serve the people to the best of our abilities in these crucial times," she added.
Eskayef's manufacturing facility is approved by many global and stringent regulatory authorities, including UK's MHRA, EU's GMP and Australia's TGA.
Eskayef recently became one of a few Asian companies to secure approval from the prestigious regulatory body -- the European Union Good Manufacturing Practice (EU GMP) -- to produce anti-cancer drugs.
The company's Oncology Manufacturing Facility is the country's first entity to have secured approval from the EU GMP.
Eskayef has been manufacturing quality medicines for the past 30 years. After serving the patients of Bangladesh, the company exports its products to 54 countries across Europe, North America, South America, Australia, Africa and Asia.
Comments